AXL Inhibition Induces DNA Damage and Replication Stress in Non–Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors

AXL, a TAM (TYRO3, AXL, and MERTK) family receptor tyrosine kinase, is increasingly being recognized as a key determinant of resistance to targeted therapies, as well as chemotherapy and radiation in non–small cell lung cancer (NSCLC) and other cancers. We further show here that high levels of AXL and epithelial-to-mesenchymal transition were frequently expressed in subsets of both treatment-naïve and treatment-relapsed NSCLC. Previously, we and others have demonstrated a role for AXL in mediating DNA damage response (DDR), as well as resistance to inhibition of WEE1, a replication stress response kinase. Here, we show that BGB324 (bemcentinib), a selective small-molecule AXL inhibitor, caused DNA damage and induced replication stress, indicated by ATR/CHK1 phosphorylation, more significantly in TP53-deficient NSCLC cell lines. Similar effects were also observed in large-cell neuroendocrine carcinoma (LCNEC) cell lines. High AXL protein levels were also associated with resistance to ATR inhibition. Combined inhibition of AXL and ATR significantly decreased cell proliferation of NSCLC and LCNEC cell lines. Mechanistically, combined inhibition of AXL and ATR significantly increased RPA32 hyperphosphorylation and DNA double-strand breaks and induced markers of mitotic catastrophe. Notably, NSCLC cell lines with low levels of SLFN11, a known predictive biomarker for platinum and PARP inhibitor sensitivity, were more sensitive to AXL/ATR cotargeting. These findings demonstrate a novel and unexpected role for AXL in replication stress tolerance, with potential therapeutic implications. Implications: These findings demonstrate that the combination of AXL and ATR inhibitors could be a promising therapeutic combination for NSCLC, LCNEC, and other cancers.

[1]  Y. Pommier,et al.  BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers , 2020, Science Translational Medicine.

[2]  V. A. Flørenes,et al.  Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma , 2019, Molecular Cancer Therapeutics.

[3]  P. Houghton,et al.  mTOR Signaling Upregulates CDC6 via Suppressing miR-3178 and Promotes the Loading of DNA Replication Helicase , 2019, Scientific Reports.

[4]  R. Torka,et al.  Targeting of the AXL receptor tyrosine kinase by small molecule inhibitor leads to AXL cell surface accumulation by impairing the ubiquitin-dependent receptor degradation , 2019, Cell Communication and Signaling.

[5]  M. Vigneron,et al.  Uniform Widespread Nuclear Phosphorylation of Histone H2AX Is an Indicator of Lethal DNA Replication Stress , 2019, Cancers.

[6]  S. Yano,et al.  AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells , 2019, Nature Communications.

[7]  D. Mutch,et al.  Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer , 2018, Molecular Cancer Therapeutics.

[8]  N. Curtin,et al.  The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation , 2018, Cancers.

[9]  A. Gemma,et al.  Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial–mesenchymal transition is critical in conquering ALK-positive lung cancer , 2018, Oncotarget.

[10]  A. Drilon,et al.  Outcomes of advanced pulmonary large cell neuroendocrine carcinoma stratified by RB1 loss, SLFN11 expression, and tumor mutational burden. , 2018 .

[11]  S. Boulton,et al.  Mechanisms of Oncogene-Induced Replication Stress: Jigsaw Falling into Place. , 2018, Cancer discovery.

[12]  M. O’Connor,et al.  Targeting the replication stress response in cancer. , 2018, Pharmacology & therapeutics.

[13]  G. Merlino,et al.  AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma , 2018, Oncogene.

[14]  I. Petersen,et al.  Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors , 2018, Nature Communications.

[15]  Y. Pommier,et al.  SLFN11 Blocks Stressed Replication Forks Independently of ATR. , 2018, Molecular cell.

[16]  P. Parren,et al.  Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors , 2018, Nature Medicine.

[17]  L. Byers,et al.  MA 02.09 A Ph I/II Study of BGB324, a Selective AXL Inhibitor as Monotherapy and in Combination with Erlotinib in Advanced NSCLC , 2017 .

[18]  Jing Wang,et al.  Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer , 2017, Clinical Cancer Research.

[19]  J. Nickoloff,et al.  Translational research in radiation-induced DNA damage signaling and repair. , 2017, Translational cancer research.

[20]  Jing Wang,et al.  Integrative Analysis Identifies a Novel AXL–PI3 Kinase–PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer , 2017, Clinical Cancer Research.

[21]  Ying Feng,et al.  Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer , 2017, Oncotarget.

[22]  L. Byers,et al.  Giving AXL the axe: targeting AXL in human malignancy , 2017, British Journal of Cancer.

[23]  A. Koong,et al.  Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies , 2017, The Journal of clinical investigation.

[24]  Jinhua Wang,et al.  mTORC1 and -2 Coordinate Transcriptional and Translational Reprogramming in Resistance to DNA Damage and Replicative Stress in Breast Cancer Cells , 2016, Molecular and Cellular Biology.

[25]  Li Shen,et al.  The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Y. Pommier,et al.  Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition , 2016, Oncotarget.

[27]  Jing Wang,et al.  AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers , 2016, Molecular Cancer Research.

[28]  C. Sima,et al.  Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. , 2016, Clinical lung cancer.

[29]  C. Rudin,et al.  PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer , 2016, Clinical Cancer Research.

[30]  Chandra Sekhar Pedamallu,et al.  Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas , 2016, Nature Genetics.

[31]  Jing Wang,et al.  Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer , 2016, PloS one.

[32]  W. Reinhold,et al.  Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs , 2015, Oncotarget.

[33]  Asier Unciti-Broceta,et al.  AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective. , 2015, Journal of medicinal chemistry.

[34]  Michael Peyton,et al.  Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. , 2015, Cancer discovery.

[35]  Pan Tong,et al.  drexplorer: A tool to explore dose-response relationships and drug-drug interactions , 2015, Bioinform..

[36]  R. Salgia,et al.  AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma , 2015, Clinical Cancer Research.

[37]  L. Franke,et al.  ATR inhibition preferentially targets homologous recombination-deficient tumor cells , 2014, Oncogene.

[38]  R. Neve,et al.  AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs. , 2014, Cancer research.

[39]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[40]  A. Sablina,et al.  p16INK4a impairs homologous recombination-mediated DNA repair in human papillomavirus-positive head and neck tumors. , 2014, Cancer research.

[41]  D. Radisky,et al.  AXL induces epithelial to mesenchymal transition and regulates the function of breast cancer stem cells , 2013, Oncogene.

[42]  Michael Peyton,et al.  An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance , 2012, Clinical Cancer Research.

[43]  S. Opiyo,et al.  Distinct roles for DNA-PK, ATM and ATR in RPA phosphorylation and checkpoint activation in response to replication stress , 2012, Nucleic acids research.

[44]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[45]  Jae Cheol Lee,et al.  Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer , 2012, Nature Genetics.

[46]  Edward S. Kim,et al.  The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.

[47]  J. Settleman,et al.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer , 2010, Oncogene.

[48]  Y. Hitoshi,et al.  R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. , 2010, Cancer research.

[49]  Alexander Pertsemlidis,et al.  Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. , 2009, Genes & development.

[50]  Jiri Bartek,et al.  An Oncogene-Induced DNA Damage Model for Cancer Development , 2008, Science.

[51]  R. Müller,et al.  Crosstalk of the mitotic spindle assembly checkpoint with p53 to prevent polyploidy , 2004, Oncogene.

[52]  T. Tong,et al.  Wild-type p16INK4a suppresses cell growth, telomerase activity and DNA repair in human breast cancer MCF-7 cells. , 2004, International journal of oncology.

[53]  Junjie Chen,et al.  Histone H2AX Is Phosphorylated in an ATR-dependent Manner in Response to Replicational Stress* , 2001, The Journal of Biological Chemistry.

[54]  S. Schreiber,et al.  ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[56]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.